Discover the latest advantages of using a personalized, tumor-informed circulating tumor DNA (ctDNA) test to design oncology clinical trials in solid tumors.
This week's FierceBiotech is brought to you by Natera.
Date: Tuesday, May 5, 2020Time: 1pm EST / 10am PSTDuration: 1 Hour
Discover the latest advantages of using a personalized, tumor-informed circulating tumor DNA (ctDNA) test to design oncology clinical trials in solid tumors. Learn how Signatera, a breakthrough technology, can be applied in early stage and late stage cancer trials, potentially enriching for patients most likely to respond to therapy, accelerating time to trial readout, or identifying early relapsers.
Want to reach 137,000+ FierceBiotech subscribers with your own message? Contact aalcover@fiercemarkets.com or call 202-824-5074.
You are currently subscribed as newsletter@newslettercollector.com. If you no longer wish to receive communications from FierceBiotech's trusted partners, simply click here to unsubscribe. Refer to our Privacy Policy.
FierceMarkets, a division of Questex, LLC 1900 L St. NW Suite 400 Washington, DC 20036
